Phase 1 Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any gender.
- People who have been diagnosed with esophageal cancer and whose doctors have recommended either pre-surgery chemotherapy combined with radiation, or chemotherapy combined with radiation as the main treatment.
- People with Stage IV (advanced) esophageal cancer that has spread only to a limited extent may also be considered, if the full medical team recommends combined chemotherapy and radiation treatment (confirm with trial site).
- People who are reasonably physically active and able to care for themselves, though not necessarily able to do heavy physical work (this is measured on a standard medical scale called ECOG, with a score of 2 or below).
- Women who are either not pregnant (confirmed by a negative pregnancy test) or who have gone through menopause, based on specific criteria related to age, hormone levels, menstrual history, or prior surgery (confirm with trial site for details).
- People who have recovered from most side effects of any previous cancer treatments, or whose remaining side effects are mild and stable.
- People who are willing and able to give informed consent to participate.
Who may not be able to join:
- People who are unable to have an MRI scan for any reason, including severe claustrophobia that cannot be managed with medication, or having certain metal objects or non-MRI-compatible medical devices inside the body (such as certain pacemakers, brain stimulators, metal fragments, or certain surgical implants).
- People who have a serious, uncontrolled illness or condition that would make combined chemotherapy and radiation treatment unsuitable, or any other condition that the trial doctor believes would make participation unsafe.
- People who have HIV with a detectable level of virus in their blood at the time of screening. Note: People with HIV who are on, or plan to start, effective HIV medication may still be considered eligible (confirm with trial site). HIV testing is not required to apply.
- People who have previously had a severe allergic reaction (classified as Grade 3 or higher on a standard medical scale) to gadolinium (a contrast dye used in MRI scans), or to FMISO (a substance used in imaging scans), or to any ingredient in these substances.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shane Lloyd, MD, Huntsman Cancer Institute
Phone: 801-585-0115
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
rate of grade ≥ 4 esophageal adverse events attributed to radiation therapy that occur within 30 days of finishing radiation therapy; rate of grade ≥ 4 esophageal adverse events attributed to radiation therapy that occur within 84 days of finishing radiation therapy; frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0), seriousness, duration, and relationship to study treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.